Blenrep (belantamab mafodotin), new option for the treatment of relapsed and refractory multiple myeloma
24 Luglio 2020
EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Blenrep (belantamab mafodotin) to treat adult patients with relapsed and
